Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elanco Animal Health (ELAN)
NYSE:ELAN
RESEARCH TOOLSreports
Holding ELAN?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.15Last Year’s EPS
$0.08Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -9.56%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there were significant achievements in innovation and debt reduction, challenges in U.S. pet health and international farm animal revenue, as well as the insolvency issue with a key supplier, posed concerns.Company Guidance
During the Elanco Animal Health Q3 2024 earnings call, the company reported strong performance metrics with organic constant currency revenue growth of 1%, adjusted EBITDA and adjusted EPS exceeding midpoints of guidance ranges. The company highlighted a 3% expected organic revenue growth for 2024, with projections of mid-single-digit growth in 2025. Debt reduction was prioritized, with net leverage expected to decrease to the mid-4x range by year's end. In terms of innovation, Elanco achieved $112 million in sales for Q3 and revised its 2024 innovation sales expectations to $420-$450 million. The company also anticipated $600-$700 million in revenue from new products in 2025, with strategic investments offsetting growth headwinds like the insolvency of a key U.K. CMO. Overall, Elanco's strategic focus on innovation and debt reduction sets a robust foundation for future growth.Strong Third Quarter Performance
Elanco reported a strong third quarter with constant currency organic top line growth and adjusted EBITDA and adjusted EPS above the midpoint of guidance ranges. Organic constant currency revenue growth was 1%.
Innovation and New Product Launches
Elanco achieved key milestones with the FDA approval of Zenrelia and Credelio Quattro, entering major markets in pet health. Experior is expected to reach blockbuster status with sales exceeding $100 million globally this year.
Debt Reduction
Elanco paid down $1.3 billion of debt in the third quarter, reducing net leverage from mid-5x to mid-4x range by the end of the year.
Positive Outlook for 2025
Elanco expects 2025 organic constant currency growth to accelerate to mid-single digits, driven by $600 million to $700 million in revenue from new products.
---
ELAN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ELAN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $12.86 | $14.50 | +12.75% |
| Aug 08, 2024 | $12.38 | $12.99 | +4.93% |
| May 08, 2024 | $13.52 | $16.89 | +24.93% |
| Feb 26, 2024 | $16.37 | $16.26 | -0.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Elanco Animal Health (ELAN) report earnings?
Elanco Animal Health (ELAN) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Elanco Animal Health (ELAN) earnings time?
Elanco Animal Health (ELAN) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELAN EPS forecast?
ELAN EPS forecast for the fiscal quarter 2024 (Q4) is $0.15.
---
